June 17th 2021
The COX-2 inhibitor Anjeso, a faster-acting injectable formulation of meloxicam, reduces opioid use after surgery.
November 18th 2014
June 13th 2013
June 12th 2013
A review of systemic lupus erythematosus and current treatment options
May 1st 2011Systemic lupus erythematosus is a multi-organ, autoimmune inflammatory disease. The annual incidence of SLE in the United States ranges from 2.0 to 7.6 cases per 100,000 persons per year. This review examines the clinical course of SLE, various treatment options, and the treatment of specific manifestations of the disease such as lupus nephritis.
Late-breaking news: FDA approves Zytiga for late-stage prostate cancer
April 29th 2011FDA has approved abiraterone acetate (Zytiga, Centocor Ortho Biotech), an oral, once-daily medication for use in combination with prednisone for the treatment of men with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel.
New analysis shows fingolimod delays progression of MS disability
April 29th 2011Fingolimod (Gilenya, Novartis) reduced the risk of disability progression in patients with relapsing-remitting multiple sclerosis, regardless of treatment history, according to a phase 3, 2-year study reported at the 63rd annual meeting of the American Academy of Neurology.
White House, FDA act to reduce opioid misuse and abuse
April 29th 2011The Obama administration recently unveiled a multiagency plan to reduce the ?epidemic? of prescription drug abuse in the United States. It will include an FDA-backed education program that zeros-in on reducing the misuse and misprescribing of opioids.
Transdermal buprenorphine effective for moderate-to-severe chronic low back pain
April 22nd 2011Transdermal buprenorphine (Butrans Transdermal System, Purdue Pharma) was superior to placebo in treating opioid-naïve patients with moderate-to-severe chronic low back pain, according to study results presented at the annual meeting of the American Academy of Pain Medicine, in National Harbor, Md.
Capsaicin patch reduces neuropathic pain of HIV-associated neuropathy
April 22nd 2011One 30-minute application of a capsaicin (8%) patch (NGX-4010, Qutenza, NeurogesX) can reduce neuropathic pain due to HIV-associated neuropathy, according to data presented here at the annual meeting of the American Academy of Pain Medicine, in National Harbor, Md.
Successful switch to transdermal buprenorphine for OA pain of the hip, knee
April 22nd 2011Conversion to a 7-day regimen of transdermal buprenorphine (Butrans Transdermal System, Purdue Pharma) from a stable regimen of hydrocodone/acetaminophen (Vicodin, Abbott) can be successful in patients with osteoarthritic pain of the hip or knee, according to a study presented at the annual meeting of the American Academy of Pain Medicine, in National Harbor, Md.
Topical diclofenac beats oral formulation in safety, tolerability
April 22nd 2011Topical diclofenac is safer and better tolerated by patients with osteoarthritis of the knee compared with the oral formulation, according to data presented here at annual meeting of the American Academy of Pain Medicine, in National Harbor, Md.
FDA approves gabapentin enacarbil for RLS
April 15th 2011FDA has approved gabapentin enacarbil (Horizant Extended-Release Tablets, GlaxoSmithKline and XenoPort), a once-daily treatment for moderate-to-severe restless legs syndrome, also known as Ekbom disease. It is the first medication in its class to be approved for this condition.
Rheumatic disease patients may require 2 doses of flu vaccine
April 8th 2011Patients with inflammatory rheumatic disease may need 2 doses of adjuvanted split influenza A vaccine to elicit the same antibody response as healthy individuals, reported a recent Swiss study published in Arthritis & Rheumatism.
Tiotropium superior to salmeterol in preventing exacerbations in COPD
April 8th 2011The anticholinergic drug tiotropium is more effective than the ?2-agonist salmeterol in preventing exacerbations in patients with moderate-to-very-severe chronic obstructive pulmonary disease, according to a multicenter European study published in the New England Journal of Medicine.